The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/10 - 1/50.
1/50 - 1/100. Detects a band of approximately 55 kDa (predicted molecular weight: 61 kDa).
Acts as guanine nucleotide exchange factor (GEF) for CDC42. Promotes formation of GPHN clusters.
Detected in brain. Detected at low levels in heart.
Involvement in disease
Defects in ARHGEF9 are a cause of startle disease with epilepsy (STHEE) [MIM:300607]; also known as hyperekplexia with epilepsy. Startle disease is a genetically heterogeneous neurologic disorder. STHE is characterized by muscular rigidity of central nervous system origin, particularly in the neonatal period, and by an exaggerated startle response to unexpected acoustic or tactile stimuli.
References for Anti-ARHGEF9 antibody - C-terminal (ab71350)
This product has been referenced in:
Simon S et al. Inter-kingdom Signaling by the Legionella Quorum Sensing Molecule LAI-1 Modulates Cell Migration through an IQGAP1-Cdc42-ARHGEF9-Dependent Pathway. PLoS Pathog11:e1005307 (2015).
Read more (PubMed: 26633832) »